Cytochrome P450 (CYP) 1A1 enzyme plays an important role in the metabolism of carcinogens, such as polycyclic aromatic hydrocarbons, nitroaromatics and arylamines.
Methods
The study examined the association of CYP1A1 Ile462Val polymorphism with the risk of developing non-small cell lung cancer in a Chinese population. We conducted a case-control study including 526 non-small cell lung cancer cases and 526 cancer-free controls. The odds ratios and 95 confidence intervals were calculated by logistic regression models.
Results
Compared with 462Ile/Ile genotype carriers, subjects with CYP1A1 462Ile/Val or Val/Val genotype had a decreased risk of developing non-small cell lung cancer with odds ratios of 0.57 (95% CI, 0.44–0.75) and 0.54 (95% CI, 0.36–0.81), respectively. When stratified by smoking status, the decreased risk of non-small cell lung cancer associated with CYP1A1 462Ile/Val or Val/Val genotype was observed among nonsmokers (OR = 0.62, 95% CI, 0.45–0.87) and among smokers (OR = 0.54, 95% CI, 0.37–0.78). When stratified by smoking-dose, the correlation between CYP1A1 genotypes and the risk of non-small cell lung cancer was detected among light smokers (OR = 0.30, 95% CI, 0.19–0.48) but not among heavy smokers (OR = 0.93, 95% CI, 0.61–1.43).
Conclusions
The CYP1A1 Ile462Val variant was associated with a low risk of developing non-small cell lung cancer in a Chinese population.
OwonikokoT.K., RaginC.C., BelaniC.P., OtonA.B., GoodingW.E., TaioliE., RamalingamS.S.: Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol, 25: 5570–5577, 2007.
2.
SherT., DyG.K., AdjeiA.A.: Small cell lung cancer. Mayo Clin Proc83: 355–367, 2008.
3.
ChappellD.B., RestifoN.P.: T cell-tumor cell: a fatal interaction?Cancer Immunol Immunother, 47: 65–71, 1998.
4.
YuP., FuY.X.: Tumor-infiltrating T lymphocytes: friends or foes?Lab Invest86: 231–245, 2006.
5.
GibbonsD.L., ByersL.A., KurieJ.M.: Smoking, p53 mutation, and lung cancer. Mol Cancer Res, 12: 3–13, 2014.
6.
Melo-FilhoC.C., BragaR.C., AndradeC.H.: Advances in methods for predicting phase I metabolism of polyphenols. Curr Drug Metab, 15: 120–126, 2014.
7.
KangJ.Y., RyuS.H., ParkS.H., ChaG.S., KimD.H., KimK.H., HongA.W., AhnT., PanJ.G., JoungY.H., KangH.S., YunC.H.: Chimeric cytochromes P450 engineered by domain swapping and random mutagenesis for producing human metabolites of drugs. Biotechnol Bioeng, 111: 1313–1322, 2014.
8.
NebertD.W., ShiZ., Galvez-PeraltaM., UnoS., DraginN.: Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences — CYP1 knockout mouse lines as a paradigm. Mol Pharmacol, 84: 304–313, 2013.
9.
ShimadaT., YunC.H., YamazakiH., GautierJ.C., BeauneP.H., GuengerichF.P.: Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol Pharmacol, 41: 856–864, 1992.
10.
BartschH., PetruzzelliS., De FloraS., HietanenE., CamusA.M., CastegnaroM., AlexandrovK., RojasM., SaracciR., GiuntiniC.: Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case-control multicenter study on lung cancer patients. Environ Health Perspect, 98: 119–124, 1992.
11.
PaineA.J.: The cytochrome P450 gene superfamily. Int J Exp Pathol72: 349–363, 1991.
12.
HacheyD.L., DawlingS., RoodiN., ParlF.F.: Sequential action of phase I and II enzymes cytochrome p450 1B1 and glutathione S-transferase P1 in mammary estrogen metabolism. Cancer Res, 63: 8492–8499, 2003.
13.
CroftsF., CosmaG.N., CurrieD., TaioliE., TonioloP., GarteS.J.: A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis, 14: 1729–1731, 1993.
14.
SmithG.B., HarperP.A., WongJ.M., LamM.S., ReidK.R., PetsikasD., MasseyT.E.: Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol Biomarkers Prev, 10: 839–853, 2001.
15.
HuangM., ChenQ., XiaoJ., ZhaoX., LiuC.: CYP1A1 Ile462Val is a risk factor for ovarian cancer development. Cytokine, 58: 73–78, 2012.
16.
Pereira SerafimP.V., Cotrim Guerreiro da SilvaI.D., Manoukias ForonesN.: Relationship between genetic polymorphism of CYP1A1 at codon 462 (Ile462Val) in colorectal cancer. Int J Biol Markers, 23: 18–23, 2008.
17.
LiraM.G., ProvezzaL., MalerbaG., NaldiL., RemuzziG., BoschieroL., ForniA., RugiuC., PiasericoS., AlaibacM., TurcoA., GirolomoniG., TessariG.: Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. Exp Dermatol, 15: 958–965, 2006.
18.
SinghV., RastogiN., SinhaA., KumarA., MathurN., SinghM.P.: A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women. Breast Cancer Res Treat, 101: 73–81, 2007.
19.
DohertyJ.A., WeissN.S., FreemanR.J., DightmanD.A., ThorntonP.J., HouckJ.R., VoigtL.F., RossingM.A., SchwartzS.M., ChenC.: Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev, 14: 357–366, 2005.
20.
LarsenJ.E., ColosimoM.L., YangI.A., BowmanR., ZimmermanP.V., FongK.M.: Risk of non-small cell lung cancer and the cytochrome P4501A1 Ile462Val polymorphism. Cancer Causes Control, 16: 579–585, 2005.
21.
SobinL.H., WittekindCh (Ed.): TNM Classification of Malignant Tumours, Sixth Edition. John Wiley & Sons Inc, New York, 2002.
22.
AkiyamaT.E., GonzalezF.J.: Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors. Biochim Biophys Acta, 1619: 223–234, 2003.
23.
HechtS.S.: Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol, 3: 461–469, 2002.
YangX.R., WacholderS., XuZ., DeanM., ClarkV., GoldB., BrownL.M., StoneB.J., FraumeniJFJr, CaporasoN.E.: CYP1A1 and GSTM1 polymorphisms in relation to lung cancer risk in Chinese women. Cancer Lett, 214: 197–204, 2004.
KawajiriK., NakachiK., ImaiK., HayashiS., WatanabeJ.: Individual differences in lung cancer susceptibility in relation to polymorphisms of P-450IA1 gene and cigarette dose. Princess Takamatsu Symp, 21: 55–61, 1990.
28.
ChangB.L., ZhengS.L., IsaacsS.D., TurnerA., HawkinsG.A., WileyK.E., BleeckerE.R., WalshP.C., MeyersD.A., IsaacsW.B., XuJ.: Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int J Cancer, 106: 375–378, 2003.
29.
LiH., XiaoD., HuL., HeT.: Association of CYP1A1 polymorphisms with prostate cancer risk: an updated meta-analysis. Mol Biol Rep, 39: 10273–10284, 2012.
30.
CoteM.L., YooW., WenzlaffA.S., PrysakG.M., SanterS.K., ClaeysG.B., Van DykeA.L., LandS.J., SchwartzA.G.: Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis, 30: 626–635, 2009.
31.
YoonK.A., KimJ.H., GilH.J., HwangH., HwangboB., LeeJ.S.: CYP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women. Lung Cancer, 60: 40–46, 2008.
32.
LucasD., MenezC., FlochF., GourlaouenY., SparfelO., JoannetI., BodénezP., JezequelJ., GouérouH., BerthouF., BardouL.G., MénezJ.F.: Cytochromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis or upper aerodigestive tract cancer in alcoholic Caucasians. Alcohol Clin Exp Res, 20: 1033–1037, 1996.
33.
HungH.C., ChuangJ., ChienY.C., ChernH.D., ChiangC.P., KuoY.S., HildesheimA., ChenC.J.: Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev, 6: 901–905, 1997.
34.
KitamuraH., YazawaT., OkudelaK., ShimoyamadaH., SatoH.: Molecular and genetic pathogenesis of lung cancer: differences between small-cell and non-small-cell carcinomas. Open Pathol J, 2: 9, 2008.
35.
KayeF.J.: RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene, 21: 6908–6914, 2002.
36.
TohC.K., GaoF., LimW.T., LeongS.S., FongK.W., YapS.P., HsuA.A., EngP., KoongH.N., ThirugnanamA., TanE.H.: Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers. Lung Cancer, 56: 161–166, 2007.
37.
JiY.N., WangQ., SuoL.J.: CYP1A1 Ile462Val polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: a meta-analysis. PLoS One, 7: e43397, 2012.
38.
RothM.D., Marques-MagallanesJ.A., YuanM., SunW., TashkinD.P., HankinsonO.: Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell Mol Biol, 24: 339–344, 2001.
39.
AnttilaS., RaunioH., HakkolaJ.: Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and cross-talk in lung carcinogenesis. Am J Respir Cell Mol Biol, 44: 583–590, 2011.
40.
OyamaT., UramotoH., KagawaN., YoshimatsuT., OsakiT., NakanishiR., NagayaH., KanekoK., MutoM., KawamotoT., TanakaF., GotohA.: Cytochrome P450 in non-small cell lung cancer related to exogenous chemical metabolism. Front Biosci (Schol Ed)4: 1539–1546, 2012.
41.
LondonS.J., DalyA.K., LeathartJ.B., NavidiW.C., CarpenterC.C., IdleJ.R.: Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis, 18: 1203–1214, 1997.
42.
XuX., KelseyK.T., WienckeJ.K., WainJ.C., ChristianiD.C.: Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev, 5: 687–692, 1996.
